Accelerating Lentiviral Vector Manufacturing With Well-Aligned Plasmid And Vector Manufacturing Platforms

By Philippe Ledent and Rakel Lopez de Maturana

To expedite the development and approval of lentiviral vectors (LVVs) for advanced therapies, it is crucial to have optimized and aligned plasmid and LVV manufacturing platforms. VIVEbiotech, a contract development and manufacturing organization (CDMO) specializing in LVV development and production, partnered with Xpress Biologics, a provider of plasmid development and manufacturing outsourcing services, to address this critical need. This is part of a broader initiative by Polyplus and Sartorius companies to explore how enhancing quality or coordinating GMP-grade materials and equipment early in processes can reduce both time and costs.